Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia
Adoption of 1-dose programs with 9-valent vaccine in an LMIC resulted in more vaccine-preventable HPV-related cancer cases than 2-dose programs. The 2-dose programs were more likely to be cost-effective than 1-dose programs for a wide range of WTP thresholds and scenarios.
Authors
- Vincent Daniels (ORCID: https://orcid.org/0000-0002-3226-7231)
- Oscar Patterson‐Lomba (ORCID: https://orcid.org/0009-0000-3764-8191)
- Andrés Gómez-Liévano (ORCID: https://orcid.org/0000-0001-8320-0857)
- Jarir At Thobari (ORCID: https://orcid.org/0000-0002-7035-4846)
- Nancy Durand (ORCID: https://orcid.org/0000-0003-2925-1922)
- Kunal Saxena (ORCID: https://orcid.org/0000-0002-2531-2305)
- Evan R. Myers (ORCID: https://orcid.org/0000-0002-9053-9864)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Universitas Gadjah Mada (ID)
- University of Toronto (CA)
- Duke Medical Center (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1371/journal.pone.0310591
- Citations
- 3
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Merck